

Radioisotope Imaging for Early Cancer Detection: A Review of Techniques and Clinical Applications

¹Abhishek, ²Fiza Ara, ³Bhalendu Upadhyay, ⁴Adarsh Kumar Dubey, ⁵Abhishek Sharma

¹Assistant Professor, ²Assistant Professor, ³Student, ⁴Student, ⁵Student

¹Department of radio-diagnosis, ²Department of radiology, ³Department of radiology, ⁴Department of radiology, ⁵Department of radiology

¹Santosh Deemed to be university, Ghaziabad, India, ²kailash institute of nursing and para-medical sciences, Greater Noida, India, ^{3,4,5}kailash institute of nursing and para-medical sciences, Greater Noida, India

Abstract

Radioisotope imaging, a pivotal field within nuclear medicine, offers unparalleled insights into the early diagnosis and management of cancer. Modalities such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) utilize radiolabelled biomarkers to capture molecular and metabolic activity at the cellular level—well before structural changes become evident. This review delves into recent innovations in radiotracer chemistry, hybrid imaging technologies, and their growing clinical relevance. Particular attention is given to the early detection of malignancies such as breast, lung, and prostate cancers, where subtle biochemical shifts frequently precede overt anatomical manifestations.

Introduction

Timely identification of cancer markedly enhances patient outcomes and the effectiveness of therapeutic interventions. (1) Conventional anatomical imaging techniques like CT and MRI typically reveal malignancies only after pronounced structural alterations have occurred. In contrast, radioisotope imaging offers a window into the molecular landscape of disease, allowing clinicians to identify cancerous processes at their earliest, most treatable stages. (2)



Figure: 1

Principles of Radioisotope Imaging

Radioisotope imaging entails the introduction of a radiopharmaceutical—an active biological compound tagged with a gamma- or positron-emitting isotope—into the patient's body. This technique primarily employs two imaging modalities:

- PET (Positron Emission Tomography), utilizing tracers such as ¹⁸F-FDG (Fluorodeoxyglucose)
- SPECT (Single Photon Emission Computed Tomography), employing isotopes like ^{99m}Tc or ¹²³I

These radiotracers preferentially localize in tissues with elevated metabolic activity, such as tumours, where their emitted radiation is detected and transformed into diagnostic images by PET scanners or gamma cameras. **(3)**

Clinical Applications

Oncology

- Facilitates the early identification and precise staging of malignant tumours
- Enables ongoing assessment of therapeutic efficacy and detection of disease recurrence.
- Utilizes FDG-PET as the diagnostic gold standard in cancers of the lung, breast, and colon. **(4)**

Cardiology

- Employs SPECT to assess myocardial blood flow and tissue viability
- Detects ischemic regions, infarctions, and evaluates risk factors associated with heart failure. **(5)**

Neurology

- Applies PET imaging for the diagnosis and monitoring of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy
- Visualizes pathological features including amyloid plaque deposition and cerebral glucose metabolism. **(6)**

Endocrinology

- Uses radioiodine tracers to evaluate thyroid gland function and detect thyroid malignancies
- Localizes parathyroid adenomas for surgical planning. **(7)**

Infection and Inflammation

- Tracks labelled leukocytes or employs gallium scans to accurately pinpoint sites of infection and inflammatory processes. **(8)**

Radiotracers in the Early Detection of Cancer

FDG-PET

- Utilizes ^{18}F -fluorodeoxyglucose (^{18}F -FDG), a glucose analogue that accumulates in tissues exhibiting heightened glycolytic activity, a characteristic feature of many malignancies.
- Predominantly applied in the diagnosis and management of lung, colorectal, and breast cancers. **(9)**

PSMA-Targeted Imaging

- Employs ligands targeting prostate-specific membrane antigen (PSMA) labelled with isotopes such as ^{68}Ga or ^{18}F , offering enhanced sensitivity for detecting prostate cancer, particularly in identifying early metastatic deposits. **(10)**

Somatostatin Receptor-Based Imaging

- Designed for neuroendocrine tumours, this technique uses ^{68}Ga -DOTATATE PET/CT to achieve precise and early localization of lesions by targeting somatostatin receptors expressed on tumour cells. **(11)**

Hybrid Imaging Techniques: PET/CT and PET/MRI

Hybrid imaging platforms seamlessly combine functional data from radioisotope tracers with detailed anatomical visualization, enhancing diagnostic precision.

- PET/CT merges metabolic information from PET with the structural clarity of CT, significantly improving lesion localization and staging accuracy.
- PET/MRI offers exceptional soft-tissue contrast alongside reduced radiation exposure, making it especially advantageous for imaging in paediatric populations and cancers of the pelvis. **(12)**

Modalities in Radioisotope Imaging

SPECT (Single Photon Emission Computed Tomography)

- Generates three-dimensional images by employing rotating gamma cameras to capture emitted photons.
- Widely utilized for cardiac perfusion studies and cerebral imaging.

PET (Positron Emission Tomography)

- Delivers superior sensitivity and spatial resolution compared to SPECT.
- Extensively used in oncology and neurological investigations.
- Frequently combined with CT or MRI to create comprehensive hybrid imaging solutions such as PET/CT and PET/MRI. **(13)**

Clinical Impact in Early Detection

Cancer-Specific Applications of Radioisotope Imaging

Lung Cancer

- FDG-PET enhances the assessment of pulmonary nodules and tumour staging, helping to minimize unnecessary surgical interventions by improving diagnostic accuracy. **(14)**

Breast Cancer

- Positron Emission Mammography (PEM) offers high-resolution detection of small tumours, including early-stage ductal carcinoma in situ (DCIS), facilitating timely and precise diagnosis. **(15)**

Prostate Cancer

- PSMA-targeted PET imaging provides superior sensitivity in identifying both localized and metastatic disease, often preceding findings from traditional imaging techniques and significantly impacting therapeutic planning. **(16)**

Challenges and Emerging Horizons in Radioisotope Imaging

While radioisotope imaging offers transformative clinical benefits, it is not without limitations:

- Concerns surrounding patient exposure to ionizing radiation remain paramount.
- The high costs and restricted accessibility of advanced imaging systems pose significant barriers, particularly in resource-limited settings.
- Limitations in tracer specificity can affect diagnostic accuracy and interpretation. (17)

Looking forward, several promising avenues are shaping the future of this field:

- The design and synthesis of highly tumour-selective radiotracers aim to improve diagnostic precision and minimize off-target uptake.
- Integration of artificial intelligence-driven image analysis holds the potential to enhance early cancer detection and streamline diagnostic workflows.
- The rise of theragnostic—combining targeted imaging with personalized radioisotope therapies—represents a paradigm shift in cancer management. (18)

Recent Innovations in Radioisotope Imaging

- **Theragnostic:** The fusion of diagnostic imaging and targeted radiotherapy, exemplified by agents like ^{77}Lu -PSMA, is revolutionizing personalized oncology.
- **Artificial Intelligence:** Advanced algorithms are improving image quality through enhanced processing and noise reduction, facilitating more accurate interpretation.
- **Target-Specific Radiotracers:** Novel compounds such as PSMA and DOTATATE are refining tumour detection with increased specificity.
- **Hybrid PET/MRI Systems:** Offering superior soft-tissue visualization with reduced radiation exposure, PET/MRI is particularly valuable in sensitive patient populations.

Conclusion

Radioisotope imaging represents a transformative approach in the early detection of cancer. Its ability to visualize metabolic and molecular changes prior to structural abnormalities positions it as a vital tool in personalized oncology.

References

1. Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., & Wender, R. C. (2018). Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*, 68(4), 297–316. <https://doi.org/10.3322/caac.21446>
2. Aide, N., Hicks, R. J., Le Tourneau, C., & Greiner, R. A. (2020). FDG PET/CT for early response assessment to chemotherapy in cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging*, 47(1), 81–96. <https://doi.org/10.1007/s00259-019-04542-5>
3. Rahmim, A., & Zaidi, H. (2008). PET versus SPECT: Strengths, limitations and challenges. *Nuclear Medicine Communications*, 29(3), 193–207. <https://doi.org/10.1097/MNM.0b013e3282f3a515>
4. Delbeke, D., & Sandler, M. P. (2004). The role of PET and PET/CT in the evaluation of cancer. *Radiologic Clinics of North America*, 42(6), 1101–1117. <https://doi.org/10.1016/j.rcl.2004.07.007>
5. Berman, D. S., Hachamovitch, R., Shaw, L. J., & Hayes, S. W. (2006). Roles of nuclear cardiology in the era of evidence-based medicine. *Journal of Nuclear Cardiology*, 13(5), 676–692. <https://doi.org/10.1016/j.nuclcard.2006.07.003>

6. Villemagne, V. L., Dore, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018). Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. *Nature Reviews Neurology*, *14*(4), 225–236. <https://doi.org/10.1038/nrneuro.2018.9>
7. Schlumberger, M., & Pacini, F. (2015). Thyroid Tumors. In *Nuclear Endocrinology* (pp. 235–250). Springer. https://doi.org/10.1007/978-3-319-22747-6_14
8. Love, C., Tomas, M. B., Tronco, G. G., & Palestro, C. J. (2005). Radionuclide imaging of infection. *Journal of Nuclear Medicine Technology*, *33*(1), 10–16. <https://tech.snmjournals.org/content/33/1/10>
9. Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., ... & Weber, W. A. (2015). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *European Journal of Nuclear Medicine and Molecular Imaging*, *42*(2), 328–354. <https://doi.org/10.1007/s00259-014-2961-x>
10. Eiber, M., Herrmann, K., Calais, J., Hadaschik, B. A., Giesel, F. L., & Maurer, T. (2021). Prostate cancer molecular imaging standardization: Joint EANM and SNMMI procedure guideline for PSMA PET imaging. *Journal of Nuclear Medicine*, *62*(4), 548–561. <https://doi.org/10.2967/jnumed.120.255754>
11. Hope, T. A., Bodei, L., Chan, J. A., El-Haddad, G., Fidelman, N., Kunz, P. L., & Mailman, J. (2019). NANETS/SNMMI consensus statement on patient selection and appropriate use of ^{68}Ga -DOTATATE PET/CT for diagnosis and staging of neuroendocrine tumors. *Journal of Nuclear Medicine*, *60*(2), 179–185. <https://doi.org/10.2967/jnumed.118.218800>
12. Hope, T. A., & Berganos, R. N. (2019). PET/MRI in oncology: Current applications and future directions. *Seminars in Roentgenology*, *54*(4), 320–327. <https://doi.org/10.1053/j.ro.2019.06.003>
13. Slomka, P. J., Pan, T., Berman, D. S., & Germano, G. (2015). Advances in SPECT and PET hardware. *Progress in Cardiovascular Diseases*, *57*(6), 566–578. <https://doi.org/10.1016/j.pcad.2015.02.004>
14. Fischer, B. M., Mortensen, J., & Høilund-Carlsen, P. F. (2009). Positron emission tomography in the diagnosis and staging of lung cancer: A systematic, quantitative review. *The Lancet Oncology*, *10*(8), 764–772. [https://doi.org/10.1016/S1470-2045\(09\)70144-2](https://doi.org/10.1016/S1470-2045(09)70144-2)
15. Berg, W. A., Madsen, K. S., Schilling, K., Tartar, M., Pisano, E. D., Larsen, L. H., ... & Narayanan, D. (2011). Breast cancer: Comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. *Radiology*, *258*(1), 59–72. <https://doi.org/10.1148/radiol.10100447>
16. Eiber, M., Herrmann, K., Calais, J., Hadaschik, B. A., Giesel, F. L., & Maurer, T. (2021). Prostate cancer molecular imaging standardization: Joint EANM and SNMMI procedure guideline for PSMA PET imaging. *Journal of Nuclear Medicine*, *62*(4), 548–561. <https://doi.org/10.2967/jnumed.120.255754>
17. Baum, R. P., Kulkarni, H. R., & Schuchardt, C. (2017). Theranostics: A new approach in nuclear medicine. *World Journal of Nuclear Medicine*, *16*(3), 125–126. <https://doi.org/10.4103/1450-1147.203406>
18. Lukyanenko, R., Wiers, C. E., & Volkow, N. D. (2021). Artificial intelligence in medical imaging: Harnessing machine learning to improve cancer diagnosis and treatment. *Trends in Cancer*, *7*(7), 617–620. <https://doi.org/10.1016/j.trecan.2021.03.002>
19. Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., ... & Haberkorn, U. (2016). PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with ^{177}Lu -PSMA-617. *Journal of Nuclear Medicine*, *57*(8), 1170–1176. <https://doi.org/10.2967/jnumed.115.170568>
20. Liew, C., & Goh, V. (2020). Artificial intelligence and radiomics in nuclear medicine: Current status and future perspectives. *Seminars in Nuclear Medicine*, *50*(4), 333–343. <https://doi.org/10.1053/j.semnuclmed.2020.03.001>